大细胞神经内分泌癌合并肺腺癌和鳞状细胞癌：病例报告及文献复习。
Combined large cell neuroendocrine carcinoma, lung adenocarcinoma, and squamous cell carcinoma: a case report and review of the literature.
机构信息
Department of Thoracic Surgery, Hainan hospital of PLA general hospital, Sanya, 572013, PR China.
Department of Pathology, Hainan hospital of PLA general hospital, Sanya, PR China.
出版信息
J Cardiothorac Surg. 2023 Aug 31;18(1):254. doi: 10.1186/s13019-023-02349-4.
BACKGROUND
Combined large cell neuroendocrine carcinoma (C-LCNEC) has a poor prognosis and there is no consensus about the treatment regimen for both LCNEC and C-LCNEC patients.
CASE PRESENTATION
The patient was a 47-year-old female who received surgical resection. The postoperative histology and staging of the tumor suggested C-LCNEC with adenocarcinoma and squamous cell carcinoma and T2aN0M0 stage IB. Next-generation sequencing test showed KIF5B/RET fusion mutation without EGFR, ALK, RB1, and TP53 alterations. Adjuvant chemotherapy with 4-cycle docetaxel plus carboplatin was given and brain metastasis occurred after 10 months.
CONCLUSIONS
C-LCNEC with adenocarcinoma and squamous cell carcinoma is rare and highly aggressive cancer. Surgical resection and adjuvant chemotherapy with SCLC regimen may improve the disease-free survival and overall survival. The accumulation of similar cases will clarify the profile and management of the disease.
背景
大细胞神经内分泌癌合并（C-LCNEC）预后较差，对于 LCNEC 和 C-LCNEC 患者的治疗方案尚无共识。
病例介绍
患者为 47 岁女性，接受了手术切除。术后组织学和肿瘤分期提示 C-LCNEC 合并腺癌和鳞状细胞癌，分期为 T2aN0M0 期 IB 级。下一代测序检测显示 KIF5B/RET 融合突变，无 EGFR、ALK、RB1 和 TP53 改变。给予 4 周期多西他赛加卡铂辅助化疗，10 个月后发生脑转移。
结论
C-LCNEC 合并腺癌和鳞状细胞癌是一种罕见且侵袭性很强的癌症。手术切除和小细胞肺癌方案的辅助化疗可能改善无病生存率和总生存率。类似病例的积累将阐明该疾病的特征和管理。
Zotero 插件